Questionnaire

1. Amendments to naming conventions in asthma research now refer to atopic asthma as:

2. New biologic therapies are available for the treatment of:

3. The SATS-recommended initial therapy for the management of steps 1/2 asthma is:

4. The SATS-recommended alternative initial therapy for the management of steps 1/2 asthma is:

5. For patients with steps 1/2 asthma and whose symptoms remain uncontrolled when using initial/alternative therapy, the SATS recommends:

6. Patients with ‘mild’ asthma using as-needed salbutamol as reliever therapy are at risk of severe exacerbation and dying from asthma:

7. Every patient with asthma should be using an ICS as part of their therapy:

8. Reported outcomes in patients who have asthma with intermittent symptoms are:

9. Compared with twice-daily ICS for the treatment of steps 1/2 asthma, as-needed ICS plus reliever therapy has demonstrated a similar rate of exacerbations, with steroid exposure lowered by:

10. Among factors that influence the best approach to asthma treatment for the individual patient are: